UOC
CLDX icon

UBS O'Connor’s Celldex Therapeutics CLDX Stock Holding History

UBS O'Connor’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-667
Closed -$157K – 451
2015
Q4 		$157K Buy
+667
New +$145K ﹤0.01% 388
2014
Q1 		– Sell
-5,000
Closed -$1.82M – 451
2013
Q4 		$1.82M Buy
+5,000
New +$1.93M 0.03% 268

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS O'Connor's CLDX Position: Q1 2016 in Review

UBS O'Connor sold out of Celldex Therapeutics (CLDX) in Q1 2016, closing a stake of 667 shares — an estimated $157K sold.

UBS O'Connor first reported a position in CLDX in Q4 2013 and held it in 2 quarters. The position peaked at $1.82M in Q4 2013. 145 funds tracked by Wall St. Rank hold CLDX as of Q1 2016.

  • UBS O'Connor reported no remaining Celldex Therapeutics position as of Q1 2016 after selling out during the quarter.
  • UBS O'Connor sold 667 Celldex Therapeutics shares in Q1 2016, an estimated $157K.
  • UBS O'Connor first reported a position in Celldex Therapeutics in Q4 2013 and held it in 2 quarters.
  • UBS O'Connor's Celldex Therapeutics position peaked at $1.82M in Q4 2013.
  • 145 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2016.

Based on UBS O'Connor's 13F filing for Q1 2016, filed 13 May 2016.